Similarly, the INTUITT-NF2 study assessed the efficacy of brigatinib in patients with neurofibromatosis type 2 (NF2)–related tumors, including vestibular schwannomas, non-vestibular schwannomas, meningiomas, and ependymomas, exemplifying how a single therapeutic strategy can be applied across multiple tumor types within the same RD spectrum [64]. This evidence concerns the gene NF2 and Vestibular schwannoma.